Northside Hospital offers new diagnostic imaging tool for the detection, staging and restaging of rare neuroendocrine tumors

A new tool available at Northside Hospital aims to locate, stage and restage rare neuroendocrine tumors (NETs) in patients, helping doctors find disease that they were unable to see before.

 

More than 12,000 people in the United States are diagnosed with NETs each year, according to the Neuroendocrine Tumor Research Foundation. NETs develop in the hormone-producing cells of the body’s neuroendocrine system.

 

Most NETs are not harmful. They often form in the intestine, pancreas or lungs, but sometimes trigger a rare form of cancer that can be difficult to diagnose with current imaging techniques.

 

The Northside Hospital Cancer Institute is one of the largest and most respected providers of cancer care services in the Southeast and treats more than 300 newly diagnosed cases of NETs year. The hospital is one of only a handful in the Southeast to offer NETSPOT®, a product recently approved by the U.S. Food and Drug Administration for the preparation of Gallium-68 (Ga-68) dotatate for PET/CT (positron emission tomography – computed tomography) imaging.

 

“NETSPOT provides a more sensitive and specific imaging tool to determine location of disease, for staging and restaging of patients with well-differentiated and moderately-differentiated NETs,” said Dr. William C. Lavely, nuclear medicine specialist at Northside Radiology Associates.

 

Ga-68 dotatate is a radioactive diagnostic agent that is specifically designed to detect somatostatin receptors, including those in NETs. When injected into the patient, the agent binds to the receptors.

 

“Somatostatin is a hormone that regulates the endocrine system and is expressed by neuroendocrine cells,” said Dr. Lavely. “This provides a unique target for neuroendocrine tumor imaging.”

 

Combined with PET/CT imaging, which offers higher resolution, three-dimensional and more rapid imaging than other imaging technologies, NETSPOT gives doctors a better picture of the disease and what they have to treat.

 

“Patients who are diagnosed with NETs early have a better chance of beating or managing the disease,” said Dr. Lavely.

 

NETSPOT is currently available at Northside Hospital imaging centers in Atlanta, Cumming, Decatur, Fayetteville and Lawrenceville.

 

About Northside Hospital (www.northside.com)

The Northside Hospital health care system is a 926-bed, not-for-profit health care provider with more than 150 locations across Georgia, including three acute care, state-of-the-art hospitals in Atlanta, Cherokee County and Forsyth County. Northside Hospital leads the U.S. in newborn deliveries, diagnoses and treats the most cancer cases in Georgia and is among the state’s top providers of surgical services. Northside has more than 2,500 physicians and 15,000 employees who serve 2.5 million patient visits annually across a full range of medical services.

 

About NETSPOT®

NETSPOT® is a patented kit developed by Advanced Accelerator Applications (AAA). NETSPOT® has been included in the National Comprehensive Cancer Network®(NCCN) Clinical Practice Guidelines in Oncology for the evaluation of neuroendocrine tumors. NETSPOT® is currently available in the U.S. in two forms: As a kit for reconstitution using a Ga-68 generator, and as NETSPOT® Injection, a ready-to-use dose delivered from a local radiopharmacy in selected metropolitan areas. The Centers for Medicare & Medicaid Services granted NETSPOT® Transitional Pass-Through status under an “A-code” (A9587) for drug reimbursement, effective January 1, 2017. The same Healthcare Common Procedure Coding System “A Code” will be used on claims to private payers. NETSPOT® has been designated as an orphan drug by the FDA. For full prescribing information for NETSPOT® please refer to: http://go.usa.gov/cSywA

 

#